Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Want to cut your energy bills? Here’s how five experts are doing it 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
NORCROSS, Ga., March 08, 2016 -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that in conjunction with the filing of its annual report on form 10-K, it will hold a business update conference call on Tuesday, March 15, 2016 at 8:30 a.m. Eastern Time. A question and answer session will be available following management’s prepared remarks.
To access the conference call, U.S.-based listeners should dial 844-236-5620 and international listeners should dial 330-863-3454. All listeners should provide the following passcode: 65873987. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company’s website at www.galectintherapeutics.com.
Following the conclusion of the conference call, a replay will be available through March 20, 2016 and can be accessed by dialing (855) 859-2056 from within the U.S. or (404) 537-3406 from outside the U.S. All listeners should provide passcode 65873987. The webcast will be available on the Company’s website at www.galectintherapeutics.com for 90 days.
About Galectin Therapeutics
Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
Contacts
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]
LHA
Kim Golodetz
(212) 838-3777
[email protected]
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.
